Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 1,551 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ulcerative Clear all

Conditions: Diabetic Foot Ulcers, Diabetes
Interventions: Topical wound dressing, Human Amnion Allograft, usual wound care; Device · Biological · Other
Lead sponsor: University of North Dakota; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Grand Forks, North Dakota

Conditions: Pressure Ulcers
Interventions: Nutritional Supplement/Amino acids and HMB, Juven; Dietary Supplement
Lead sponsor: Central Arkansas Veterans Healthcare System; Federal
Eligibility: 21 Years to 90 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Ulcerative Colitis
Interventions: Andecaliximab, Placebo to match Andecaliximab; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 6
States / cities: Monroe, Louisiana • Bethesda, Maryland • Chesterfield Township, MI 48047, Michigan + 3 more

Conditions: Gastric Ulcer
Interventions: PN400 (VIMOVO), Diclofenac/Misoprostol; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Diabetes Complications, Diabetes, Diabetic Foot Ulcer, Wound Infection
Interventions: Telcare 2.0 BGM; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy, Skin Ulcer
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 999 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ulcerative Colitis
Interventions: Catered diet, Diet guidance sessions, Dietary counseling, Feedback sessions; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 16 Years to 75 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Ulcerative Colitis
Interventions: Etrasimod, Placebo; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 62
States / cities: Dothan, Alabama • Mobile, Alabama • Sun City, Arizona + 54 more

Conditions: Venous Stasis Ulcers
Interventions: Novel Dressing; Device
Lead sponsor: Hollister Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 8
States / cities: Phoenix, Arizona • Miami, Florida • Elk Grove Village, Illinois + 4 more

Conditions: Systemic Sclerosis, Scleroderma
Interventions: treprostinil diethanolamine, placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 24
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 21 more

Conditions: Ulcerative Colitis
Interventions: Etrasimod; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 896 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 133
States / cities: Dothan, Alabama • Lake Elsinore, California • Lancaster, California + 44 more

Conditions: Pressure Ulcer
Interventions: Fluid Immersion Simulation System, Air Fluidized Bed System; Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetic Foot Ulcer, Foot Ulcer Chronic, DFU, Ulcer Foot, Venous Leg Ulcer (VLU), Venous Leg Ulcer, Venous Ulcer, Leg Ulcers, Ulcer
Interventions: Tri-Membrane Wrap™ DFU, Membrane Wrap™ DFU, Membrane Wrap-Lite™ DFU, Membrane Wrap-Hydro™ DFU, Tri-Membrane Wrap™ VLU, Membrane Wrap™ VLU, Membrane Wrap-Lite™ VLU, Membrane Wrap-Hydro™ VLU; Other
Lead sponsor: BioLab Holdings; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philidelphia, Pennsylvania

Conditions: Keratitis Bacterial
Interventions: Moxifloxacin Ophthalmic, Difluprednate Ophthalmic, Riboflavin Ophthalmic, Topical Placebo; Drug · Other
Lead sponsor: Thomas M. Lietman; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: San Francisco, California • Miami, Florida

Conditions: Crohn's Disease, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: New York, New York • Chapel Hill, North Carolina

Conditions: Ulcerative Colitis
Interventions: Standard of care; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lower Extremity Wound Infected, Venous Stasis Ulcers
Interventions: VAC VeraFlo with Dakins Instillation, VAC Ulta Therapy; Device
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Ulcerative Colitis
Interventions: placebo, rhuMAb Beta7; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 8
States / cities: San Diego, California • Gainesville, Florida • Atlanta, Georgia + 5 more

Conditions: Ulcerative Colitis
Interventions: SHR0302, Placebo; Drug
Lead sponsor: Reistone Biopharma Company Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 23
States / cities: Dothan, Alabama • Lancaster, California • New Haven, Connecticut + 19 more

Conditions: Ulcerative Colitis
Interventions: Visilizumab (Nuvion®; HuM291); Drug
Lead sponsor: PDL BioPharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 15
States / cities: San Francisco, California • Gainesville, Florida • Atlanta, Georgia + 11 more

Conditions: Ulcerative Colitis
Interventions: infliximab; Biological
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more

Conditions: Diabetes Mellitus, Foot Ulcer, Ulcer, Diabetic Foot Ulcer, Wound, Wound Heal
Interventions: No interventions; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 4
States / cities: Indianapolis, Indiana • Columbus, Ohio

Conditions: Spinal Cord Injuries
Interventions: SCI Virtual Coach; Behavioral
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Foot Ulcer
Interventions: OptiPulse™, Standard of Care offloading device; Device
Lead sponsor: Compedica Inc; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 18
States / cities: Phoenix, Arizona • Los Angeles, California • Vista, California + 12 more

Search by objective public record fields.

A Comparison of TCC-EZ Using Human Amnion Allograft vs TCC-EZ and Standard Wound Care in Treating Diabetic Foot Ulcers.

Effect of an Oral Supplement Enriched in Amino Acids and the Leucine Metabolite B-hydroxy B-methylbutyrate (HMB)

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec

Diabetic Foot Ulcer and Wound Infection

Pathophysiology of Chronic Wounds

Tailored Anti-Inflammatory (A-I) Diet for Americans With Ulcerative Colitis (UC)

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

Wound Fluid Protease Levels During Use of Novel Wound Dressing

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

Fluid Immersion Simulation (FIS) System Versus Air Fluidized Bed (AFB) System for Pressure Ulcers

Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers

Steroids and Cross-linking for Ulcer Treatment

Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)

Multi-center Acute Severe Ulcerative Colitis Cohort Study (MASCC)

V.A.C. VeraFlo™ Instillation Therapy vs V.A.C. Ulta™ Therapy on Biofilm in Chronically Infected Wounds

Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis

miR-200b & miR-21 in Diabetic Wounds

Spinal Cord Injury Virtual Coach RCT

A Clinical Investigation Evaluating Wound Closure With OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's